1. Re-evaluation of progenitor thresholds and expectations for haematopoietic recovery based on an analysis of 810 autologous transplants: Implications for quality assurance
- Author
-
Andrew Antonio, David C. Linch, Michael J. Watts, Simon Hack, Carmen Balsa, and SJ Ings
- Subjects
Adult ,Male ,Time Factors ,Transplantation Conditioning ,Adolescent ,Quality Assurance, Health Care ,Cell ,CD34 ,030204 cardiovascular system & hematology ,Transplantation, Autologous ,Andrology ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Cell dose ,Humans ,Medicine ,Progenitor cell ,Aged ,Progenitor ,business.industry ,Platelet recovery ,Graft Survival ,Hematopoietic Stem Cell Transplantation ,Hematology ,Middle Aged ,Hematopoietic Stem Cells ,Blood Cell Count ,Hematopoiesis ,Haematopoiesis ,Treatment Outcome ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Female ,business ,Quality assurance - Abstract
Haematological engraftment was assessed in 804 autologous transplants. Neutrophil recovery occurred in over 99% within 14 d but platelet recovery was delayed beyond this time in 14·8%. Time to recovery was dependent on the progenitor cell dose infused. The minimum CD34+ cell threshold adopted in this study (2 × 106 /kg) was safe although recovery was faster with a dose >5 × 106 /kg. CD34+ cell doses of between 1 and 2 × 106 /kg were also acceptable if either the granulocyte-macrophage colony-forming cell dose exceeded 2 × 105 /kg or this dose was due to splitting a higher yield harvest. Prompt neutrophil recovery affords important quality assurance for laboratory processing.
- Published
- 2016
- Full Text
- View/download PDF